`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`PAR PHARMACEUTICAL, INC.,
`
`Petitioner
`
`v.
`
`HORIZON THERAPEUTICS, LLC,
`
`Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2017-01767
`Patent 9,254,278
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PATENT OWNER’S INITIAL EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.63 (e), the Patent Owner hereby provides an
`
`initial exhibit list:
`
`Exhibit
`No.
`
`Description
`
`2001
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`RESERVED.
`
`Notice of Allowance dated December 23, 2015, Prosecution History
`of U.S. Patent No. Patent 9,254,278.
`
`Dixon et al., “Intercurrent Illness in Inborn Errors of Intermediary
`Metabolism, 67 Archives of Disease in Childhood, 1387-1391 (1992)
`(“Dixon”).
`
`Rani H. Singh, et al., “Nutritional Management of Urea Cycle
`Disorders,” Crit. Care. Clin. 21:S27-35 (2005). (“Singh”).
`
`Portion of Par Pharmaceutical, Inc.’s Initial Invalidity Contentions
`and Non-Infringement Contentions for U.S. Pat. Nos. 8,404,215 and
`8,642,012 (pgs. 16-22), Hyperion Therapeutics, Inc. v. Par
`Pharmaceutical, Inc., C.A. No. 2:14-cv-00384 (JRG)(RSP) (E.D.
`Tex.)
`
`Declaration of Dr. Gregory M. Enns, M.D.
`
`Curriculum vitae of Dr. Gregory M. Enns, M.D.
`
`Ari Auron, Patrick D. Brophy, “Hyperammonemia in Review:
`Pathophysiology, Diagnosis, and Treatment,” Pediatric Nephrology,
`27:207-22 (2012). (“Auron”).
`
`2009 Mark L. Batshaw, et al., “Alternative Pathway Therapy for Urea
`Cycle Disorders: Twenty Years Later,” J. Pediatrics, 38:S46-S55
`(2001). (“Batshaw”).
`
`2010
`
`Nancy E. Maestri, et al., “Prospective Treatment of Urea Cycle
`Disorders,” J. of Pediatrics, 119:923-28, no. 6 (1991). (“Maestri”).
`
`IPR2017-01767
`
`
`
`
`Page 1
`
`
`
`2011
`
`Nancy E. Maestri, et al., “Plasma Glutamine Concentration: A Guide
`in the Management of Urea Cycle Disorders,” J. Pediatrics, 121:259–
`61, no. 2 (1992). (“Maestri 1992”).
`
`2012
`
`U.S. Patent Publication 2012/0022157 A1, filed August 27, 2009,
`published January 26, 2012. (“’157 App”).
`
`2013 Mendel Tuchman & Mark L. Batshaw, “Management of Inherited
`Disorders of Ureagenesis,” The Endocrinologist 12:99–109, no. 2
`(2002). (“Tuchman”).
`
`2014
`
`
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`
`2020
`
`Guoyao Wu, “Amino Acids: Metabolism, Functions, and Nutrition,”
`Amino Acids 37:1–17 (2009). (“Wu”).
`
`Alexander Broomfield & Stephen Grunewald, “How to use Serum
`Ammonia,” Archives of Disease in Childhood—Education and
`Practice 97:72–77 (2012). (“Broomfield”).
`
`Fumino Endo, et al., “Clinical Manifestations of Inborn Errors of the
`Urea Cycle and Related Metabolic Disorders During Childhood,” J.
`Nutrition 134:1605S–09S (2004). (“Endo”).
`
`Gregory M. Enns, “Nitrogen Sparing Therapy Revisited 2009,”
`Molecular Genetics and Metabolism 100:S65–S71 (2010). (“Enns
`2010”).
`
`Takhar Kasumov, et al., “New Secondary Metabolits of
`Phenylbutyrate in Humans and Rats,” Drug Metabolim and
`Disposition, 32:10–19 (2004) (“Kasumov”).
`
`Johannes Häberle, et al., “Suggested Guidelines for the Diagnosis and
`Management of Urea Cycle Disorders,” Orphanet J. Rare Diseases,
`7:32, 1–30 (2012). (“Häberle”).
`
`Johannes Häberle, “Clinical Practice: The Management of
`Hyperammonemia,” Eur. J. of Pediatrics 170:21–34 (2011).
`(“Häberle Clinical”).
`
`2021
`
`J.V. Leonard & A. A. M. Morris, “Urea Cycle Disorders,” Seminars
`in Neonatology 7:27–35 (2002). (“Leonard 2002”).
`
`IPR2017-01767
`
`
`
`Page 2
`
`
`
`2022
`
`Ann-Kaisa Niemi & Gregory M. Enns, “Sodium Phenylacetate and
`Sodium Benzoate in the Treatment of Neonatal Hyperammonemia,”
`NeoReviews, 7:e486–e95, no. 9 (2006). (“Niemi”).
`
`2023 Marshall Summar & Mendel Tuchman, “Proceedings of a Consensus
`Conference for the Management of Patients with Urea Cycle
`Disorders,” J. Pediatrics, 138:S6–S10 (2001). (“Summar”).
`
`2024
`
`2025
`
`2026
`
`2027
`
`2028
`
`2029
`
`Saul W. Brusilow & Nancy E. Maestri, “Urea Cycle Disorders:
`Diagnosis, Pathophysiology, and Therapy,” Advances in Pediatrics
`43:127–70 (1996). (“Brusilow 1996”).
`
`Colloquium, “Consensus Statement from a Conference for the
`Management of Patients with Urea Cycle Disorders,” J. Pediatrics,
`Supplement 1, 138:S1–S5 (2001). (“Consensus”).
`
`“Specialties of Genetics,” Am. Board of Medical Genetics and
`Genomics (last accessed Jan. 17, 2017),
`http://abmgg.org/pages/training_specialties.shtml. (“ABMGG”).
`
`“About Us,” Urea Cycle Disorders Consortium (last accessed Oct.
`25, 2017), https://www.rarediseasesnetwork.org/cms/ucdc/About-Us.
`
`Gregory M. Enns, et al., “Survival After Treatment with
`Phenylacetate and Benzoate for Urea-Cycle Disorders,” The New
`England Journal of Medicine 356:2282–92 (2007). (“Enns”).
`
`Gregory M. Enns & Tina M. Cowan, “Hyperammonemia,” in Signs
`and Symptoms of Genetic Conditions: A Handbook, ch. 18, 261–279
`(Louanne Hudgins et al., eds., 2014). (“Enns 2014”).
`
`2030 Michael Msall, et al., “Neurologic Outcome in Children with Inborn
`Errors of Urea Synthesis,” The New England Journal of Medicine
`310:1500–1505 (1984). (“Msall”).
`
`2031
`
`B.D. Cheson, et al., “Novel Therapeutic Agents for the Treatment of
`Myelodysplastic Syndromes,” in Seminars in Oncology, 27:560–77,
`no. 5 (John W. Yarbro, et al. eds., 2000). (“Cheson”).
`
`IPR2017-01767
`
`
`
`Page 3
`
`
`
`2032
`
`2033
`
`Fernando Scaglia, et al., “Effect of Alternative Pathway Therapy on
`Branched Chain Amino Acid Metabolism in Urea Cycle Disorder
`Patients,” Molecular Genetics and Metabolism, Supplement 1,
`81:S79-S85 (2004). (“Scaglia”).
`
`Saul W. Brusilow & Arthur L. Horwich, “Urea Cycle Enzymes,” in
`The Online Metabolic and Molecular Bases of Inherited Disease, Ch.
`85, pp. 1–89 (David Valle et al. eds., 2015). (“Brusilow Online”).
`
`2034 Marshall Summar, “Current Strategies for the Management of
`Neonatal Urea Cycle Disorders,” J. Pediatrics 138:S30–S39 (2001).
`(“Summar 2001”).
`
`2035 Marshall L. Summar, et al., “The Incidence of Urea Cycle Disorders,”
`Molecular Genetics and Metabolism 110:179–180 (2013). (“Summar
`2013”).
`
`2036 Marshall L. Summar, et al., “Diagnosis, Symptoms, Frequency and
`Mortality of 260 Patients with Urea Cycle Disorders from a 21-Year,
`Multicentre Study of Acute Hyperammonaemic Episodes,” Acta
`Paediatrica 97:1420–25 (2008). (“Summar 2008”).
`
`Bridget Wilcken, “Problems in the Management of Urea Cycle
`Disorders,” Molecular Genetics and Metabolism 81:S86–S91 (2004).
`(“Wilcken”).
`
`Information About FDA-Approved Drug, Buphenyl,
`http://www.accessdata.fda.gov/scripts/cder/daf/ (search Drug Name,
`Active Ingredient, or Application Number field for “020572”, last
`accessed Feb. 9, 2017)
`
`Gregory M. Enns, “Neurologic Damage and Neurocognitive
`Dysfunction in Urea Cycle Disorders,” Seminars in Pediatric
`Neurology, 15:132-139 (2008). (“Enns 2008”).
`
`Ravicti® product insert,
`https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s
`005lbl.pdf. (“Ravicti Label”).
`
`2037
`
`2038
`
`2039
`
`2040
`
`
`
`
`IPR2017-01767
`
`
`
`Page 4
`
`
`
`
`Date: November 6, 2017
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
` By: / Matthew C. Phillips /
`Matthew C. Phillips
`Registration No. 43,403
`Backup Counsel for Patent Owner
`
`IPR2017-01767
`
`
`
`Page 5
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on November 6, 2017, copies of the foregoing PATENT
`
`OWNER’S INITIAL EXHIBIT LIST and all documents filed with it were served
`
`via electronic mail, as agreed to by counsel, upon the following counsel for the
`
`Petitioners:
`
`David G. Silverstein: dsilverstein@axinn.com
`Dan Feng Mei: dmei@axinn.com; Ravicti@axinn.com
`
`
`Dated: November 6, 2017
`
`
`
`
`
`By: / Matthew C. Phillips /
`Matthew C. Phillips
`Registration No. 43,403
`Backup Counsel for Patent Owner
`
`
`
`IPR2017-01767
`
`
`
`Page 6
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
